Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 35 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

7 trials in Phase 3/4

Results Transparency

0%

0 of 24 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

Phase 1
23(65.7%)
Phase 3
7(20.0%)
Phase 2
5(14.3%)
35Total
Phase 1(23)
Phase 3(7)
Phase 2(5)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (35)

Showing 20 of 35 trials
NCT07460284Phase 1Not Yet Recruiting

A Mass Balance Study Of 14C-RAY1225 Injection In Healthy Chinese Participants

Role: lead

NCT05835752Phase 1Completed

The Safety, Tolerability and Pharmacokinetic Study of RAY1225

Role: lead

NCT07362030Phase 1Active Not Recruiting

Drug-durg Interaction of RAY1225 With Warfarin, Atorvastatin, Metformin and Digoxin

Role: lead

NCT07229820Phase 3Active Not Recruiting

Efficacy and Safety of ZSP1273 in Children 12-17 Years Old With Influenza A

Role: lead

NCT07229807Phase 3Active Not Recruiting

Efficacy and Safety of ZSP1273 in Children 2-11 Years Old With Influenza A

Role: lead

NCT06656026Phase 2Completed

Pharmacokinetics,Safety and Efficacy of ZSP1273 in Children 2-17 Years Old With Influenza A

Role: lead

NCT07139535Phase 3Not Yet Recruiting

A Study of RAY1225 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

Role: lead

NCT07139548Phase 3Not Yet Recruiting

A Study of RAY1225 Versus Semaglutide as Add-on Therapy to Oral Antidiabetic Drugs in Participants With Type 2 Diabetes

Role: lead

NCT06254274Phase 2Active Not Recruiting

A Study of RAY1225 in Participants With Type 2 Diabetes

Role: lead

NCT06893016Phase 3Recruiting

Evaluation of RAY1225 in Adult Participants Who Have Obesity or Are Overweight

Role: lead

NCT05873426Phase 1Completed

Mass Balance Study of [14C]ZSP1273 in Healthy Adult Male Subjects in China

Role: lead

NCT05692492Phase 2Active Not Recruiting

A Randomized, Double-blind, Placebo-controlled Study of ZSP1601 in Adult Subjects With Nonalcoholic Steatohepatitis (NASH)

Role: lead

NCT05119972Phase 1Completed

Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Role: lead

NCT06577428Phase 1Completed

A Study of RAY1225 at Different Injection Sites in Participants With Different Body Sizes

Role: lead

NCT06577415Phase 1Recruiting

A Study of RAY1225 in Participants With Impaired Liver Function

Role: lead

NCT06248567Phase 1Completed

Pharmacokinetics of ZSP1273 in Participants With Severe Kidney Disease

Role: lead

NCT06254261Phase 2Recruiting

A Study of RAY1225 in Participants With Obesity

Role: lead

NCT06613763Phase 1Completed

A Study of RAY1225 in Participants With Impaired Kidney Function

Role: lead

NCT06362460Phase 1Completed

Mass Balance Study of [14C]RAY1216 in Healthy Adult Male Subjects in China

Role: lead

NCT06169085Phase 1Completed

Pharmacokinetics of Leritrelvir(Ray1216) in Elder Participants

Role: lead